Daily Sepsis Research Analysis
Analyzed 23 papers and selected 3 impactful papers.
Summary
Three papers stood out today: a mechanistic JCI study identifies estrogen receptor β (ERβ) deficiency as a driver of macrophage pyroptosis and sepsis susceptibility; a large NEJM RCT shows high-flow nasal cannula does not reduce 28-day mortality in acute hypoxemic respiratory failure but modestly lowers intubation; and a multi-omics Mendelian randomization study links gut microbiota–driven metabolites to sepsis, with two metabolites improving survival in mice.
Research Themes
- Host susceptibility and immunometabolism in sepsis
- Respiratory support strategies in acute hypoxemic respiratory failure
- Microbiome–metabolite causal pathways and therapeutic leads
Selected Articles
1. Estrogen receptor β deficiency increases susceptibility to sepsis through metabolic reprogramming-induced macrophage pyroptosis.
Human and animal data show ERβ expression is reduced in sepsis and its deficiency drives macrophage pyroptosis via enhanced fatty acid oxidation, increased acetyl-CoA, and Stoml2 K221 acetylation. Genetic disruption of this acetylation site rescues mitochondrial function and improves survival in septic mice, identifying ERβ deficiency as a susceptibility factor.
Impact: This study uncovers a previously unrecognized ERβ–immunometabolism–pyroptosis axis that mechanistically links host genetics to sepsis susceptibility, with a clear rescue strategy. It offers concrete, druggable targets (ERβ, FAO, Stoml2 acetylation) for precision immunomodulation.
Clinical Implications: ERβ expression could serve as a biomarker for sepsis susceptibility or risk stratification. Selective ERβ modulators or interventions targeting FAO/acetylation pathways may prevent macrophage pyroptosis and improve outcomes, warranting translational studies.
Key Findings
- ERβ expression is significantly reduced in peripheral blood of sepsis patients and inversely correlates with disease severity.
- ERβ deficiency enhances fatty acid oxidation, elevates acetyl-CoA, and promotes Stoml2 K221 acetylation, triggering mitochondrial dysfunction and macrophage pyroptosis.
- Mutating Stoml2 K221 mitigates pyroptosis-related dysfunction and improves survival in septic mice, implicating ERβ deficiency as a genetic susceptibility factor.
Methodological Strengths
- Multi-system validation combining human samples, murine models, and mechanistic perturbation of Stoml2 acetylation.
- Clear causal chain from metabolic reprogramming to pyroptosis with functional survival rescue in vivo.
Limitations
- Clinical causality and generalizability are not established; human genetic variation in ESR2 was not detailed.
- Therapeutic translatability of ERβ modulation and safety profiles require dedicated preclinical and clinical studies.
Future Directions: Validate ERβ as a prognostic/diagnostic biomarker, test selective ERβ modulators or FAO/acetylation pathway inhibitors, and examine sex-specific and genotype–phenotype effects in diverse sepsis cohorts.
Understanding susceptibility factors of sepsis is crucial for early diagnosis and development of personalized treatment strategies. However, the genetic determinants for initiation and progression of sepsis remain unclear. Here, we showed that the expression levels of estrogen receptor (ER) β are significantly reduced in the peripheral blood of sepsis patients, which were negatively correlated with disease severity. The results from human samples and experimental animals demonstrated that ERβ deficiency enhances the body's susceptibility to sepsis by inducing macrophage pyroptosis, thereby impairing bacterial clearance. Mechanistically, ERβ deficiency enhanced fatty acid oxidation, increased acetyl-CoA levels, and promoted acetylation of stomatin-like protein 2 (Stoml2) at K221, leading to mitochondrial dysfunction and macrophage pyroptosis. Mutating the Stoml2 K221 site mitigated these effects and improved survival of septic mice. These findings suggest ERβ deficiency as a potential genetic factor in sepsis susceptibility.
2. High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure.
In a multicenter RCT of 1110 patients with acute hypoxemic respiratory failure, high-flow nasal oxygen did not reduce 28-day mortality versus standard oxygen but modestly reduced intubation. Serious adverse events during spontaneous breathing were slightly more frequent with high-flow oxygen.
Impact: Provides high-level evidence clarifying the mortality-neutral effect of high-flow oxygen in acute hypoxemic respiratory failure, a frequent phenotype in sepsis, while quantifying a small reduction in intubation.
Clinical Implications: Do not expect mortality benefit from high-flow oxygen in acute hypoxemia; use it to potentially reduce intubation with attention to safety. Patient selection and close monitoring for adverse events remain essential.
Key Findings
- 28-day mortality was identical between high-flow and standard oxygen groups (both 14.6%).
- Intubation by day 28 was modestly lower with high-flow oxygen (42.4% vs 48.4%; absolute difference −5.93 percentage points; 95% CI, −11.78 to −0.08).
- Serious adverse events (cardiac arrest or pneumothorax) occurred in 2.3% with high-flow vs 1.1% with standard oxygen.
Methodological Strengths
- Large, multicenter randomized controlled design with clear eligibility and hard clinical endpoints.
- Pre-specified primary endpoint (28-day mortality) and clinically meaningful secondary outcomes (intubation, adverse events).
Limitations
- Open-label design may influence clinical decision-making (e.g., intubation thresholds).
- Study not powered to detect small differences in specific subgroups; heterogeneity of AHRF etiologies.
Future Directions: Identify phenotypes that may benefit from high-flow (e.g., specific gas-exchange or work-of-breathing profiles), evaluate protocols minimizing adverse events, and explore combined strategies with noninvasive ventilation.
BACKGROUND: Data are needed on the effect of oxygen delivered through a high-flow nasal cannula, as compared with standard oxygen therapy, on intubation and mortality in patients with acute hypoxemic respiratory failure. METHODS: In this multicenter, open-label trial, we randomly assigned patients who had acute hypoxemic respiratory failure to receive high-flow-oxygen or standard-oxygen therapy. All the patients had a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen of 200 or less, a respiratory rate of more than 25 breaths per minute, and pulmonary infiltrate on chest imaging. The primary outcome was death by day 28. RESULTS: A total of 1116 patients underwent randomization. Of these patients, 1110 (556 in the high-flow-oxygen group and 554 in the standard-oxygen group) were included in the analysis. Mortality at day 28 was 14.6% (in 81 of 556 patients) in the high-flow-oxygen group and 14.6% (in 81 of 554 patients) in the standard-oxygen group (difference, -0.05 percentage points; 95% confidence interval [CI], -4.21 to 4.10; P = 0.98). The incidence of intubation by day 28 was 42.4% (in 236 of 556 patients) in the high-flow-oxygen group and 48.4% (in 268 of 554 patients) in the standard-oxygen group (difference, -5.93 percentage points; 95% CI, -11.78 to -0.08). Serious adverse events (cardiac arrest or pneumothorax) occurred during spontaneous breathing in 13 patients (2.3%) in the high-flow-oxygen group and in 6 patients (1.1%) in the standard-oxygen group. CONCLUSIONS: Among patients with acute hypoxemic respiratory failure, the use of oxygen delivered through a high-flow nasal cannula did not significantly reduce mortality at day 28. (Funded by the French Ministry of Health and Fisher and Paykel Healthcare; SOHO ClinicalTrials.gov number, NCT04468126.).
3. A systematic exploration of gut microbiota-driven blood metabolites in sepsis: an integrated bioinformatics and genetic association study.
Two-sample and two-step MR identified gut microbiota taxa, blood metabolites, and 15 mediating metabolites linking microbes to sepsis risk (3.7–13.7% mediation). Network and docking prioritized targets, and two metabolites (gulonic acid, 4-HPA) improved survival and reduced injury and inflammation in septic mice.
Impact: Establishes a causal microbiome–metabolite–sepsis axis using genetic instruments and validates actionable metabolites in vivo, bridging human causal inference with therapeutic leads.
Clinical Implications: Supports development of microbiome- or metabolite-based interventions (e.g., supplementation with 4-HPA/GA or modulation of responsible taxa) and suggests metabolite panels for risk stratification, pending human validation.
Key Findings
- Identified 23 gut microbiota taxa and 169 circulating metabolites associated with sepsis via two-sample MR.
- Two-step MR showed 15 metabolites mediating microbe–sepsis causal links with 3.70%–13.70% mediation proportions.
- Gulonic acid and 4-hydroxyphenylacetic acid improved survival and reduced organ injury and inflammation in murine sepsis.
Methodological Strengths
- Use of two-sample and two-step Mendelian randomization to infer causality and mediation while minimizing confounding.
- Triangulation with network analyses, molecular docking, and in vivo pharmacodynamic validation.
Limitations
- MR assumptions (instrument validity, no pleiotropy) may not fully hold; mediation proportions were modest.
- Human interventional evidence is lacking; generalizability depends on underlying GWAS ancestries and datasets.
Future Directions: Validate metabolite mediators and targets in prospective human cohorts, test metabolite supplementation or microbiome modulation in early-phase trials, and dissect cell-type–specific mechanisms.
INTRODUCTION: Alterations in the blood metabolome are closely associated with sepsis, while the gut microbiota (GM) plays a crucial role in modulating both sepsis progression and circulating metabolites. However, whether the effects of the GM on sepsis are mediated through blood metabolites remains unclear. METHODS: To determine whether the effects of the GM on sepsis are mediated through blood metabolites, we performed a two-sample Mendelian randomization (MR) analysis combined with a two-step MR framework to identify potential metabolic mediators. Comprehensive bioinformatics analyses were integrated to construct interaction networks using Cytoscape, and pharmacodynamic experiments were conducted in a murine sepsis model. RESULTS: We identified 23 GM taxa and 169 blood metabolites significantly associated with sepsis. Two-step MR analysis revealed that 15 metabolites mediated the causal relationships between 12 GM taxa and sepsis, with mediation proportions ranging from 3.70% to 13.70%. A total of 131 potential molecular targets were predicted for these metabolites, and network analysis highlighted five key metabolites and seven central targets. Molecular docking demonstrated strong binding affinities between these metabolites and their targets. Notably, gulonic acid (GA) and 4-hydroxyphenylacetic acid (4-HPA), driven by Lentisphaerae, Lentisphaeria, and Victivallales, significantly improved survival and attenuated organ injury and inflammation in septic mice. DISCUSSION: Collectively, this study provides evidence supporting a causal role of the GM in sepsis, which mediated in part by blood metabolites. These findings highlight the therapeutic potential of targeting both the GM and GM-driven metabolites as novel interventions for sepsis.